Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5.3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.S.
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Telix and maintained a $20.00 price target after the company completed enrollment in the BiPASS trial and reported alignment with the U.S. Food and Drug Administration on a regulatory pathway.
The rating and price target represent the analyst’s assessment and do not establish the future performance or value of Telix shares.
BiPASS Phase 3 Trial Completes Enrollment
Telix completed enrollment of 350 patients in its Phase 3 BiPASS trial.
The study is evaluating the company’s Illuccix and Gozellix products in combination with magnetic resonance imaging compared with the standard of care for detecting prostate cancers.
Telix also reached alignment with the FDA on a New Drug Application pathway for BiPASS.
According to the supplied information, approval under this pathway would support reimbursement as a new product and could broaden patient access. Regulatory approval has not yet been granted, and the eventual outcome of the application cannot be established from the current information.
Analyst Discusses Current Prostate Cancer Diagnostic Process
Burns said that under the current diagnostic approach, men with elevated prostate-specific antigen levels may be recommended for an MRI, which can produce inconclusive results.
A prostate template biopsy, typically involving between 12 and 20 needle biopsies, may then be performed, including in some patients assessed as being at low risk based on MRI results.
According to the analyst, the biopsy procedure can fail to detect some clinically significant prostate cancers and may involve pain and complications.
Burns also noted that more than 1 million prostate biopsies are performed annually in the U.S., with as many as 75% producing negative results. He added that one in four patients decline a recommended biopsy.
These figures and assessments represent information provided by the analyst in the supplied material and are not independently established here.
Telix Seeks Additional Diagnostic Option
Burns said the limitations associated with the existing diagnostic process support the potential role of a less invasive and more precise alternative.
BiPASS is evaluating whether the combination of Telix’s imaging products and MRI can provide an additional approach to prostate cancer detection compared with the current standard of care.
The trial’s eventual results and any subsequent regulatory decision will determine whether the approach can advance through the proposed FDA pathway.
Telix shares gained 5.3% in premarket trading following the recent trial and regulatory developments and the analyst commentary, although the supplied information does not establish the extent to which any individual factor was responsible for the share-price movement.